SCHEMBL20615705

SCHEMBL20615705

CC(C)(C)OC(=O)N1CCC([C@H](N)c2ccccc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.57
KDM4E B2RXH2 1/20 0.52
PKM P14618 1/20 0.52
DPP4 P27487 1/20 0.52
MMP13 P45452 3/20 0.51
MMP1 P03956 1/20 0.51
NPC1 O15118 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50
HTT P42858 1/20 0.50
RAB9A P51151 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
STS P08842 1/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30702475 1.00 GPR119 (0.57) GPR119KDM4EPKMDPP4MMP13
SCHEMBL2553057 1.00 GPR119 (0.57) GPR119KDM4EPKMDPP4MMP13
SCHEMBL21848082 0.92 GPR119 (0.53) GPR119KDM4EPKMDPP4MMP13
SCHEMBL22558670 0.88 GPR119 (0.59) GPR119KDM4EPKMMMP13MMP1
SCHEMBL1405370 0.88 GPR119 (0.59) GPR119KDM4EPKMMMP13MMP1
SCHEMBL30702478 0.87 ALDH1A1 (0.54) GPR119DPP4NPC1ALDH1A1MAPT
SCHEMBL6148439 0.87 MMP13 (0.54) GPR119DPP4MMP13NPC1ALDH1A1
SCHEMBL4130151 0.87 ALDH1A1 (0.54) GPR119DPP4NPC1ALDH1A1MAPT
SCHEMBL30702487 0.87 ALDH1A1 (0.54) GPR119DPP4NPC1ALDH1A1MAPT
SCHEMBL13897657 0.87 DPP4 (0.53) GPR119DPP4MMP13NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4565323-A1 AROMATIC COMPOUNDS FOR USE AS PROTEIN PHOSPHATASE 2A (PP2A) MODULATORS Rappta Therapeutics Oy (FI) 2025-06-11 EP disclosed
WO-2024028808-A1 AROMATIC COMPOUNDS FOR USE AS PROTEIN PHOSPHATASE 2A (PP2A) MODULATORS RAPPTA THERAPEUTICS OY (FI) 2024-02-08 WO disclosed
US-10927078-B2 Modulators of indoleamine 2,3-dioxygenase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-02-23 US disclosed
US-20200165201-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-05-28 US disclosed
WO-2019003141-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200165201-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, TPH1 GPR119 41/4885KDM4E 657/4885PKM 892/4885
US-10927078-B2 Modulators of indoleamine 2,3-dioxygenase IDO1, IDO2, TPH1 GPR119 41/4885KDM4E 657/4885PKM 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.